Opposing Functions of Maspin Are Regulated by Its Subcellular Localization in Lung Squamous Cell Carcinoma Cells

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 14

PMID 39272867

Authors

Takahiro Matsushige

Tomohiko Sakabe

Hirotoshi Mochida

Yoshihisa Umekita

Affiliations

Soon will be listed here.

Abstract

Mammary serine protease inhibitor (maspin) is a tumor suppressor protein downregulated during carcinogenesis and cancer progression; cytoplasmic-only maspin expression is an independent, unfavorable prognostic indicator in patients with lung squamous cell carcinoma (LUSC). We hypothesized that the cytoplasmic-only localization of maspin has tumor-promoting functions in LUSC. The subcellular localization of maspin and the invasive capability of LUSC cell lines were investigated using RNA sequencing (RNA-seq), Western blotting, and siRNA transfection. Maspin mRNA and protein expression were suppressed in LK-2 and RERF-LC-AI cells. Cell invasion significantly increased in response to siRNA-mediated maspin knockdown in KNS-62 cells expressing both nuclear and cytoplasmic maspin. In LK-2 cells, both nuclear and cytoplasmic maspin were re-expressed, and cell invasion and migration were significantly decreased. In contrast, re-expressed maspin in RERF-LC-AI cells was detected only in the cytoplasm (cytMaspin), and cell invasion and migration were significantly promoted. RNA-seq and downstream analyses revealed that increased cytMaspin expression downregulated the genes associated with cell adhesion and activated PYK2 and SRC, which play important roles in cancer progression. Our study demonstrates a novel biological function of cytMaspin in enhancing the invasive capabilities of LUSC cells. Understanding cytoplasm-to-nuclear maspin translocation dysregulation may develop novel therapeutic approaches to improve the prognosis of patients with LUSC.

References

Latha K, Zhang W, Cella N, Shi H, Zhang M . Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol. 2005; 25(5):1737-48. PMC: 549349. DOI: 10.1128/MCB.25.5.1737-1748.2005. View

Matsuoka Y, Takagi Y, Nosaka K, Sakabe T, Haruki T, Araki K . Cytoplasmic expression of maspin predicts unfavourable prognosis in patients with squamous cell carcinoma of the lung. Histopathology. 2016; 69(1):114-20. DOI: 10.1111/his.12921. View

Sun C, Ng K, Lim Z, Cheng Q, Lo C, Poon R . Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS One. 2011; 6(4):e18878. PMC: 3080371. DOI: 10.1371/journal.pone.0018878. View

Suarez-Arnedo A, Torres Figueroa F, Clavijo C, Arbelaez P, Cruz J, Munoz-Camargo C . An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS One. 2020; 15(7):e0232565. PMC: 7386569. DOI: 10.1371/journal.pone.0232565. View

Tamazato Longhi M, Cella N . Tyrosine phosphorylation plays a role in increasing maspin protein levels and its cytoplasmic accumulation. FEBS Open Bio. 2013; 2:93-7. PMC: 3642124. DOI: 10.1016/j.fob.2012.04.006. View

Zou Z, Gao C, Nagaich A, Connell T, Saito S, Moul J . p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem. 2000; 275(9):6051-4. DOI: 10.1074/jbc.275.9.6051. View

Dotto G, Rustgi A . Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. Cancer Cell. 2016; 29(5):622-637. PMC: 4870309. DOI: 10.1016/j.ccell.2016.04.004. View

Desai A, Adjei A . FGFR Signaling as a Target for Lung Cancer Therapy. J Thorac Oncol. 2016; 11(1):9-20. DOI: 10.1016/j.jtho.2015.08.003. View

Lau S, Pan Y, Velcheti V, Wong K . Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer Cell. 2022; 40(11):1279-1293. DOI: 10.1016/j.ccell.2022.09.018. View

10.

Goulet B, Kennette W, Ablack A, Postenka C, Hague M, Mymryk J . Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest. 2011; 91(8):1181-7. DOI: 10.1038/labinvest.2011.66. View

11.

Sakabe T, Wakahara M, Shiota G, Umekita Y . Role of cytoplasmic localization of maspin in promoting cell invasion in breast cancer with aggressive phenotype. Sci Rep. 2021; 11(1):11321. PMC: 8166868. DOI: 10.1038/s41598-021-90887-z. View

12.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

13.

Longhi M, Silva L, Pereira M, Magalhaes M, Reina J, Vitorino F . PI3K-AKT, JAK2-STAT3 pathways and cell-cell contact regulate maspin subcellular localization. Cell Commun Signal. 2021; 19(1):86. PMC: 8364028. DOI: 10.1186/s12964-021-00758-3. View

14.

Alam M, Hasan G, Eldin S, Adnan M, Riaz M, Islam A . Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. Biomed Pharmacother. 2023; 161:114452. DOI: 10.1016/j.biopha.2023.114452. View

15.

Woenckhaus M, Bubendorf L, Dalquen P, Foerster J, Blaszyk H, Mirlacher M . Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer. J Clin Pathol. 2006; 60(5):483-6. PMC: 1994526. DOI: 10.1136/jcp.2005.033407. View

16.

Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-1357. DOI: 10.1016/S0140-6736(21)02098-5. View

17.

Zou Z, Anisowicz A, Hendrix M, Thor A, Neveu M, Sheng S . Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 1994; 263(5146):526-9. DOI: 10.1126/science.8290962. View

18.

Wendt M, Schiemann B, Parvani J, Lee Y, Kang Y, Schiemann W . TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene. 2012; 32(16):2005-15. PMC: 3721373. DOI: 10.1038/onc.2012.230. View

19.

Dabiri S, Moeini Aghtaei M, Shahryari J, Shamis Meymandi M, Amirpour-Rostami S, Foutohi Ardekani R . Maspin Gene Expression in Invasive Ductal Carcinoma of Breast. Iran J Pathol. 2016; 11(2):104-11. PMC: 4939639. View

20.

Avizienyte E, Frame M . Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol. 2005; 17(5):542-7. DOI: 10.1016/j.ceb.2005.08.007. View